Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this first-in-man study is to evaluate the safety of 188Re-PTI-6D2 in patients
with metastatic melanoma. All patients will receive a tracer dose of 188Re-PTI-6D2 in order
to provide information on how the monoclonal antibody is distributed throughout the body and
to assess tumor targeting. No therapeutic dose of radiation will be given in the first study.